Therapy Detail

Therapy Name MK2206 + Romidepsin
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MK2206 MK-2206 Akt Inhibitor (Pan) 17 MK2206 binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation (PMID: 20571069).
Romidepsin Istodax FK228|FR901228|NSC 630176|depsipeptide HDAC Inhibitor 34 Istodax (romidepsin) inhibits Class I HDACs, resulting in cell cycle arrest, apoptosis, and decreased tumor cell growth (PMID: 12208741, PMID: 12234611, PMID: 21258344). Istodax (romidepsin) is FDA approved for patients with cutaneous T-cell lymphoma (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mutant Advanced Solid Tumor sensitive MK2206 + Romidepsin Preclinical Actionable In a preclinical study, treatment with the combination of MK2206 and Istodax (romidepsin) resulted in greater cell death in tumor cell lines harboring Kras mutations compared to cell lines with wild-type Kras (Cancer Res April 15, 2012 72:4708) detail...
Clinical Trial Phase Therapies Title Recruitment Status